Our Mission

Activities in support of this mission include

• Convene meetings of leading bioscientists to foster collaboration and formulation of coordinated, programmatic research plans.
• Establish a blueprint for a specific step-by-step research agenda that exploits new cellular models and assays of brain function as well as new classes of medicines which can specifically target expression of key pathways that regulate CNS plasticity.
• Raise funds to support this research agenda and distribute these funds based on rigorous peer review of applications for funding from academic and commercial investigators.
• Encourage research partnerships between scientists in academic and business settings to explore the potential of anti-sense oligonucleotides (ASOs) and small molecule medicines to accelerate brain recovery, particularly in the context of rigorous therapy services and repletion of key populations of CNS cells.
• Promote research efforts to evaluate the safety and efficacy of various treatment regimens utilizing genomically targeted nucleic acid medicines (ASOs) and/or small molecule medicines to promote neurological recovery in the chronic phase following TBI.
• Link with other TBI information and advocacy groups and organizations to disseminate information regarding ongoing research efforts in pioneering medicines to improve outcomes for persons with severe TBI.
• Provide support to neuroscientists pursuing research into innovative pharmaceutical approaches to TBI recovery via information, references, professional linkages, and review and consultation regarding grant applications.